Arthur Allen, Gregory Piazza, Margaret Fang/LinkedIn
Sep 12, 2025, 15:44
Long-Term Apixaban Use for Provoked VTE: Focus on HI-PRO Trial by Arthur Allen, Margaret Fang and Gregory Piazza
Anticoagulation Forum shared on LinkedIn:
”Join us for our free October webinar: Emerging Evidence: Long-term oral anticoagulation following provoked VTE? A focus on the HI-PRO Trial
Tuesday, October 7, 2025 | 12:00 PM ET
Join us as expert faculty review findings from the recent HI-PRO Trial on the use of apixaban for extended treatment of provoked venous thromboembolism (VTE).
What you’ll learn:
- Key insights from trial design and results
- Clinical implications for real-world practice
- Patient selection considerations for extended therapy
Faculty:
Arthur Allen, PharmD, CACP – Salt Lake City Va Health Care System
Margaret Fang, MD, MPH – University of California, San Francisco
Gregory Piazza, MD, MS – Brigham and Women’s Hospital”
Register here.
Stay informed on all webinars and seminars in the field of thrombosis with Hemostasis Today.
-
Sep 12, 2025, 06:39Chokri Ben Lamine: Approach to Intra-Operative Bleeding in G6P Deficiency – Key Causes and Management
-
Sep 11, 2025, 15:42The True Price of Gene Therapy: Breaking Down Beqvez’s $3.5M Cost and What Really Drives It
-
Sep 11, 2025, 14:49Samantha Nelson Shares "The Beat" - World Thrombosis Day Just Added Newsletter to LinkedIn
-
Sep 11, 2025, 13:01Do Not Miss ISTH Fast Five! Pediatric and Neonatal Thrombosis & Hemostasis and Many More Webinars
-
Sep 11, 2025, 08:33Alfonso J. Tafur Shares VascuLearn’s Free Virtual Support Groups This Fall for Patients and Providers
-
Sep 12, 2025, 06:21Flora Peyvandi on Why Plasminogen Activation Is Not Required to Prevent Venous Thrombosis
-
Sep 12, 2025, 03:38Haematologica Early View: Omid Seidizadeh Explores Genetics Behind Clinical Variability in Type 2 VWD
-
Sep 11, 2025, 15:03Rapid ADAMTS13 Assays: A Key Milestone in the 100 Years of Innvoation in TTP Diagnosis - Silvio Castagni
-
Sep 11, 2025, 14:25Thrombin Generation Assays to Assess COC-Associated Procoagulant Alterations
-
Sep 11, 2025, 13:55Transplantation-Mediated Alloimmune Thrombocytopenia: Mostafa Faisal Mohammed Saleh Presents a Rare Case
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 11, 2025, 15:27Postpartum Haemorrhage: In Kenya, More than 120 Mothers Die for Every 100,000 Live Births
-
Sep 11, 2025, 15:11Join the Global Effort: World Thrombosis Day Campaign for Healthcare and Community Organizations
-
Sep 11, 2025, 14:26José Antonio García Erce: Self-Sufficiency in Blood Products - Utopia or Reality?
-
Sep 11, 2025, 08:08Al-Ola A Abdallah on MGUS-Related Bleeding Disorders
-
Sep 10, 2025, 19:32Denis Brutus Oduor: Call for Altruism in Blood Donation in Nairobi
Sep 12, 2025, 16:11
Sep 12, 2025, 05:27